
Market Analysis
As of 2024, the global Gene Silencing Market is valued at approximately USD 4.63 billion and is projected to reach around USD 9.09 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 7.75% during the forecast period .
This growth is attributed to the increasing prevalence of genetic disorders, advancements in gene silencing technologies, and rising investments in research and development.

Competitor Analysis

Alnylam Pharmaceuticals
Benitec Biopharma
Arrowhead Pharmaceuticals
Merck Group
Eli Lilly (Dicerna Pharmaceuticals)
